التفاصيل البيبلوغرافية
| العنوان: |
Table_1_Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.docx |
| المؤلفون: |
Francesco Autore, Luca Stirparo, Idanna Innocenti, Elena Papa, Francesco Marchesi, Chiara Togni, Sabrina Mariani, Lorenzo Torrieri, Martina Salvatori, Francesca Fazio, Elisabetta Metafuni, Sabrina Giammarco, Federica Sora, Paolo Falcucci, Antonella Ferrari, Silvia Maria Trisolini, Saveria Capria, Agostino Tafuri, Patrizia Chiusolo, Simona Sica, Luca Laurenti |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, SARSC-CoV-2, vaccination, autologous stem cell transplant (ASCT), efficacy, rituximab |
| الوصف: |
COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/Table_1_Immunogenicity_of_SARS-CoV-2_vaccination_in_patients_undergoing_autologous_stem_cell_transplantation_A_multicentric_experience_docx/21664850Test |
| DOI: |
10.3389/fonc.2022.897937.s003 |
| الإتاحة: |
https://doi.org/10.3389/fonc.2022.897937.s003Test
https://figshare.com/articles/dataset/Table_1_Immunogenicity_of_SARS-CoV-2_vaccination_in_patients_undergoing_autologous_stem_cell_transplantation_A_multicentric_experience_docx/21664850Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.7B5D35D4 |
| قاعدة البيانات: |
BASE |
